
Merus Labs International Inc. (TSE:MSL – Free Report) (NASDAQ:MSLI) – Equities research analysts at HC Wainwright cut their FY2026 earnings per share estimates for shares of Merus Labs International in a report released on Friday, November 13th. HC Wainwright analyst A. He now anticipates that the specialty pharmaceutical company will earn ($2.85) per share for the year, down from their prior estimate of ($2.69). HC Wainwright also issued estimates for Merus Labs International’s Q4 2026 earnings at ($0.55) EPS, Q2 2027 earnings at ($0.64) EPS, Q3 2027 earnings at ($0.67) EPS, Q4 2027 earnings at ($0.70) EPS, FY2027 earnings at ($2.63) EPS, FY2028 earnings at ($2.61) EPS, FY2029 earnings at ($1.22) EPS and FY2030 earnings at $1.24 EPS.
Separately, Craig Hallum upgraded Merus Labs International to a “strong-buy” rating in a report on Thursday, October 8th. Four equities research analysts have rated the stock with a Strong Buy rating and one has issued a Buy rating to the stock. According to data from MarketBeat, Merus Labs International has a consensus rating of “Strong Buy”.
Get Our Latest Stock Analysis on MSL
Merus Labs International Stock Performance
Merus Labs International has a 1-year low of C$0.95 and a 1-year high of C$1.76.
About Merus Labs International
Merus Labs International Inc. is a specialty pharmaceutical company. The Company is engaged in the acquisition and licensing of branded prescription pharmaceutical products. The Company’s products include Elantan, Isoket, Deponit, Sintrom, Emselex/Enablex, Surgestone, Provames, Speciafoldine, Tredemine, Salagen, Estraderm MX and Vancocin. Elantan are tablets or capsules that belong to a group of medicines called organic nitrates. Isoket belongs to a group of medicines called organic nitrates. Deponit belongs to a group of medicines called nitrates.
Read More
- Five stocks we like better than Merus Labs International
- Microsoft’s Outage Barely Moved Its Stock, But a Bigger Risk May Be Building
- MongoDB’s Biggest Advantage May Be GitLab’s Biggest Weakness
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
Receive News & Ratings for Merus Labs International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus Labs International and related companies with MarketBeat.com's FREE daily email newsletter.
